Browse PMEPA1

Summary
SymbolPMEPA1
Nameprostate transmembrane protein, androgen induced 1
Aliases solid tumor-associated 1; TMEPAI; transmembrane, prostate androgen induced RNA; prostate transmembrane prote ......
Chromosomal Location20q13.31-q13.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Early endosome membrane; Single-pass membrane protein. Golgi apparatus membrane; Single-pass membrane protein.
Domain -
Function

Functions as a negative regulator of TGF-beta signaling and thereby probably plays a role in cell proliferation, differentiation, apoptosis, motility, extracellular matrix production and immunosuppression. In the canonical TGF-beta pathway, ZFYVE9/SARA recruits the intracellular signal transducer and transcriptional modulators SMAD2 and SMAD3 to the TGF-beta receptor. Phosphorylated by the receptor, SMAD2 and SMAD3 then form a heteromeric complex with SMAD4 that translocates to the nucleus to regulate transcription. Through interaction with SMAD2 and SMAD3, LDLRAD4 may compete with ZFYVE9 and SMAD4 and prevent propagation of the intracellular signal (PubMed:20129061, PubMed:24627487). Also involved in down-regulation of the androgen receptor (AR), enhancing ubiquitination and proteasome-mediated degradation of AR, probably by recruiting NEDD4 (PubMed:18703514).

> Gene Ontology
 
Biological Process GO:0001933 negative regulation of protein phosphorylation
GO:0007178 transmembrane receptor protein serine/threonine kinase signaling pathway
GO:0007179 transforming growth factor beta receptor signaling pathway
GO:0007183 SMAD protein complex assembly
GO:0009755 hormone-mediated signaling pathway
GO:0010990 regulation of SMAD protein complex assembly
GO:0010991 negative regulation of SMAD protein complex assembly
GO:0017015 regulation of transforming growth factor beta receptor signaling pathway
GO:0030512 negative regulation of transforming growth factor beta receptor signaling pathway
GO:0030518 intracellular steroid hormone receptor signaling pathway
GO:0030521 androgen receptor signaling pathway
GO:0030522 intracellular receptor signaling pathway
GO:0031333 negative regulation of protein complex assembly
GO:0042326 negative regulation of phosphorylation
GO:0043254 regulation of protein complex assembly
GO:0043401 steroid hormone mediated signaling pathway
GO:0048545 response to steroid hormone
GO:0060389 pathway-restricted SMAD protein phosphorylation
GO:0060393 regulation of pathway-restricted SMAD protein phosphorylation
GO:0060394 negative regulation of pathway-restricted SMAD protein phosphorylation
GO:0071383 cellular response to steroid hormone stimulus
GO:0071396 cellular response to lipid
GO:0071407 cellular response to organic cyclic compound
GO:0071559 response to transforming growth factor beta
GO:0071560 cellular response to transforming growth factor beta stimulus
GO:0090092 regulation of transmembrane receptor protein serine/threonine kinase signaling pathway
GO:0090101 negative regulation of transmembrane receptor protein serine/threonine kinase signaling pathway
GO:0090287 regulation of cellular response to growth factor stimulus
GO:0090288 negative regulation of cellular response to growth factor stimulus
GO:1903844 regulation of cellular response to transforming growth factor beta stimulus
GO:1903845 negative regulation of cellular response to transforming growth factor beta stimulus
Molecular Function GO:0046332 SMAD binding
GO:0050699 WW domain binding
GO:0070412 R-SMAD binding
Cellular Component GO:0005769 early endosome
GO:0010008 endosome membrane
GO:0031901 early endosome membrane
GO:0044440 endosomal part
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-2173788: Downregulation of TGF-beta receptor signaling
R-HSA-162582: Signal Transduction
R-HSA-170834: Signaling by TGF-beta Receptor Complex
R-HSA-2173789: TGF-beta receptor signaling activates SMADs
Summary
SymbolPMEPA1
Nameprostate transmembrane protein, androgen induced 1
Aliases solid tumor-associated 1; TMEPAI; transmembrane, prostate androgen induced RNA; prostate transmembrane prote ......
Chromosomal Location20q13.31-q13.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between PMEPA1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolPMEPA1
Nameprostate transmembrane protein, androgen induced 1
Aliases solid tumor-associated 1; TMEPAI; transmembrane, prostate androgen induced RNA; prostate transmembrane prote ......
Chromosomal Location20q13.31-q13.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of PMEPA1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolPMEPA1
Nameprostate transmembrane protein, androgen induced 1
Aliases solid tumor-associated 1; TMEPAI; transmembrane, prostate androgen induced RNA; prostate transmembrane prote ......
Chromosomal Location20q13.31-q13.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of PMEPA1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-1.2280.016
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-1.3960.421
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-1.1120.434
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.1060.829
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.3910.831
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.7170.793
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.4640.407
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.2670.861
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.7630.633
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.8420.617
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.980.41
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.4680.0186
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of PMEPA1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27730001
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211714.35.98.40.613
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131115.49.16.31
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91622.26.2160.53
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 592011.18.91
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47250250.364
1329033130MelanomaallAnti-PD-1 (nivolumab) 3827011.1-11.10.067
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 221307.7-7.70.371
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1614014.3-14.30.209
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolPMEPA1
Nameprostate transmembrane protein, androgen induced 1
Aliases solid tumor-associated 1; TMEPAI; transmembrane, prostate androgen induced RNA; prostate transmembrane prote ......
Chromosomal Location20q13.31-q13.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of PMEPA1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolPMEPA1
Nameprostate transmembrane protein, androgen induced 1
Aliases solid tumor-associated 1; TMEPAI; transmembrane, prostate androgen induced RNA; prostate transmembrane prote ......
Chromosomal Location20q13.31-q13.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of PMEPA1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by PMEPA1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolPMEPA1
Nameprostate transmembrane protein, androgen induced 1
Aliases solid tumor-associated 1; TMEPAI; transmembrane, prostate androgen induced RNA; prostate transmembrane prote ......
Chromosomal Location20q13.31-q13.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of PMEPA1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolPMEPA1
Nameprostate transmembrane protein, androgen induced 1
Aliases solid tumor-associated 1; TMEPAI; transmembrane, prostate androgen induced RNA; prostate transmembrane prote ......
Chromosomal Location20q13.31-q13.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of PMEPA1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolPMEPA1
Nameprostate transmembrane protein, androgen induced 1
Aliases solid tumor-associated 1; TMEPAI; transmembrane, prostate androgen induced RNA; prostate transmembrane prote ......
Chromosomal Location20q13.31-q13.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between PMEPA1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolPMEPA1
Nameprostate transmembrane protein, androgen induced 1
Aliases solid tumor-associated 1; TMEPAI; transmembrane, prostate androgen induced RNA; prostate transmembrane prote ......
Chromosomal Location20q13.31-q13.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting PMEPA1 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.